Evidence map›Paper›PMID 37877536›Full record

ArticleBiotechnology and bioengineering2024

Identification and characterization of CHO host-cell proteins in monoclonal antibody bioprocessing.

Young Hoon Oh, Kerri M Mendola, Leila H Choe, Lie Min, Ashton R Lavoie, Sobhana A Sripada, Taufika Islam Williams, Kelvin H Lee, Yinges Yigzaw, Alexander Seay and 6 more

Open access · greenAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Young Hoon OhDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.
Kerri M MendolaDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.
Leila H ChoeDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.
Lie MinDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.
Ashton R LavoieDepartment of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina, USA.ORCID 0000-0001-9842-8520
Sobhana A SripadaDepartment of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina, USA.ORCID 0000-0003-2011-8527
Taufika Islam WilliamsMolecular Education, Technology, and Research Innovation Center (METRIC), North Carolina State University, Raleigh, North Carolina, USA.
Kelvin H LeeDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.ORCID 0000-0003-0908-2981
Yinges YigzawPurification Process Development, Genentech, Inc., South San Francisco, California, USA.
Alexander SeayPurification Process Development, Genentech, Inc., South San Francisco, California, USA.
Jerome BillPurification Process Development, Genentech, Inc., South San Francisco, California, USA.
Xuanwen LiAnalytical Research and Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
David J RoushBPR&D, Merck & Co., Inc., Kenilworth, New Jersey, USA.ORCID 0000-0001-8841-7043
Steven M CramerDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.ORCID 0000-0003-4635-5221
Stefano MenegattiDepartment of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina, USA.ORCID 0000-0001-5633-434X
Abraham M LenhoffDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, USA.ORCID 0000-0002-7831-219X
University of Delaware · USNorth Carolina State University · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USRensselaer Polytechnic Institute · US

Funding

Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI MELINDA K DUNCAN · 2012 to 2026
$67.2M
Data Management and Storage System for Shared Resource FacilitiesS10OD028725 · OD · UNIVERSITY OF DELAWARE · PI POLSON, SHAWN W · 2021 to 2021
$600k
NIGMS NIH HHS P20 GM103446NIH HHS S10 OD028725
6 · The paper itself

Abstract

Host-cell proteins (HCPs) are the foremost class of process-related impurities to be controlled and removed in downstream processing steps in monoclonal antibody (mAb) manufacturing. However, some HCPs may evade clearance in multiple purification steps and reach the final drug product, potentially threatening drug stability and patient safety. This study extends prior work on HCP characterization and persistence in mAb process streams by using mass spectrometry (MS)-based methods to track HCPs through downstream processing steps for seven mAbs that were generated by five different cell lines. The results show considerable variability in HCP identities in the processing steps but extensive commonality in the identities and quantities of the most abundant HCPs in the harvests for different processes. Analysis of HCP abundance in the harvests shows a likely relationship between abundance and the reproducibility of quantification measurements and suggests that some groups of HCPs may hinder the characterization. Quantitative monitoring of HCPs persisting through purification steps coupled with the findings from the harvest analysis suggest that multiple factors, including HCP abundance and mAb-HCP interactions, can contribute to the persistence of individual HCPs and the identification of groups of common, persistent HCPs in mAb manufacturing.

Indexed as

Antibodies, MonoclonalAnimalsCHO CellsCricetinaeCricetulusHumansMass SpectrometryReproducibility of ResultsAntibodies, MonoclonalbioprocessingChinese hamster ovary cellshost-cell proteinsmonoclonal antibodiespurification

Identifiers

PMID37877536
PMCPMC10842603
OpenAlexW4387930707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.